New option listings for January 24th include TCDAQ Stock (TCDAQ). Option delistings effective January 24th include ABIOMED Inc (ABMD), Altimeter Growth 2 Corp (AGCB), Bright Lights Acquisition Corp (BLTS), Concord
New option listings for January 24th include TCDAQ Stock (TCDAQ). Option delistings effective January 24th include ABIOMED Inc (ABMD), Altimeter Growth 2 Corp (AGCB), Bright Lights Acquisition Corp (BLTS), Concord
PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s
Oyster Point Pharma announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to
Reports Q3 revenue $5.59M, consensus $13.93M. "We are pleased with third quarter results while establishing TYRVAYA as the first and only nasal spray available as a treatment option for patients
PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the quarter ended